Letteratura scientifica selezionata sul tema "Annual meeting (1916 : St. Louis, Mo.)"

Abstract The purpose of our article is to present the results of our treatment of dural arteriovenous fistula of the cavernous sinus by glue embolization of the external carotid artery feeders. By this case presentation we try to clarify the clinical course, with the dural carotid cavernous fistula (CCF), characterizing a pallet of symptoms, paying special attention to radiological finding and endovascular treatment. Dural arteriovenous fistulas represent 10% to 15% of all intracranial arteriovenous malformations (A. Fox, G. Duckwiler, “Dural Arteriovenous Fistula,” presented at the annual meeting of the American Society of Neuroradiology, St Louis, Mo, June 1992). Dural arteriovenous fistulas are rare clinical situation, especially examples involving the cavernous sinus. Most dural fistulas are acquired conditions, typically occurring in postmenopausal women, but sometimes in other patients in association with other condition [1,3]. These dural fistulas are most often “spontaneous” cavernous carotid shunts (usually low-flow) [2, 4, 5], usually related to a past trauma or surgery. The classical triad, represented by pulsating exophthalmos, conjunctival chemosis, and pulsatile-tinnitus are well-known clinical symptoms of these lesions but are not necessary present in the majority of the patients as first indicators. The anatomy of these vascular malformations consists of multiple arterial feeders flowing into cavernous sinus. The arterial feeders are usually meningeal branches arising from the internal carotid artery (ICA) or the external carotid artery (ECA). However, there are few reports of large series [1], and the clinical entity is not widely known. The purpose of this paper is to present a clinical case of a patient with dural cavernous sinus fistulae, clarify the clinical symptoms course and special attention to results of endovascular treatment.

Abstract Background: Steroid hormones influence breast tissue development and play a role in breast carcinogenesis. Their associations with mammographic breast density (MBD), an established risk factor for breast cancer, are less clear. We, therefore, investigated the associations of steroid hormone metabolites with MBD in premenopausal women. Methods: Our study population consists of 705 premenopausal women recruited during their annual screening mammogram at the Washington University School of Medicine, St. Louis, MO. We assessed volumetric percent density (VPD), dense volume (DV), and non-dense volume (NDV) using Volpara. We assayed 54 steroid hormone metabolites from fasting blood samples at Metabolon. Linear regression models were used, after adjusting for covariates, to estimate the least square means of VPD, DV, and NDV across tertiles (T) of each metabolite. Sensitivity analysis was performed among the subset of participants with a history of oral contraceptive use (OCP). We used the Benjamini-Hochberg procedure to correct for multiple tests to control the false discovery rate (FDR) at a 5% level. Results: Five androgen metabolites (androstenediol (3beta,17beta) monosulfate 2, androstenediol (3beta,17beta) disulfate 1, 5alpha-androstan-3alpha,17beta-diol monosulfate 2, 5alpha-androstan-3alpha,17beta-diol disulfate, and 5alpha-androstan-3beta,17beta-diol disulfate) and two corticosteroid metabolites (tetrahydrocortisone glucuronide 5, and cortolone glucuronide 1) were inversely associated with VPD. Androstenediol (3beta,17beta) disulfate 1, and 5alpha-androstan-3alpha,17beta-diol disulfate displayed the strongest associations with VPD. The mean VPD decreased across tertiles of androstenediol (3beta,17beta) disulfate 1 from 9.0% in T1 to 8.5% in T2, and 7.5% in T3 (FDR p-value=0.02). Similarly, the mean VPD decreased from 8.8% in T1 to 8.4% in T2, and 7.6% in T3 of 5alpha-androstan-3alpha,17beta-diol disulfate (FDR p-value=0.03). Progestin steroid metabolites appeared to be positively associated with VPD but only 5alpha-pregnan-3beta,20alpha-diol monosulfate 2 was marginally significant after FDR correction (7.5% in T1, 8.3% in T2, and 8.8% in T3; FDR p-value=0.06). Four metabolites (three corticosteroids and one androgenic steroid) were positively associated with NDV. No metabolite was associated with DV. In sensitivity analysis limited to OCP users, mean VPDs were lower but the directions of associations were similar to those observed in the overall analysis. Conclusion: We report novel associations of corticosteroids and androgen metabolites with breast density in premenopausal women. Our findings shed important new insights into hormonal biomarkers and MBD. Citation Format: Kayode A. Matthew, Girish K. Vanapali, Kayla R. Getz, Myung S. Jeon, Chongliang Luo, Xingyi Guo, Jingqin Luo, Adetunji T. Toriola. Steroid hormone metabolites and mammographic breast density in premenopausal women [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4431.

Abstract Introduction: High mammographic breast density (MBD) is a strong risk factor for breast cancer, but the biological mechanisms underlying high MBD are not well understood. We, therefore, comprehensively investigated for the first time the associations of lipid species with volumetric measures of MBD to elucidate potential biological mechanisms of high MBD in premenopausal women. Methods: We performed lipidomic profiling on 705 premenopausal women recruited during their annual screening mammogram at Washington University School of Medicine, St. Louis, MO. Lipidomic profiling for 982 lipid species was completed at Metabolon (Durham, NC®). Lipid species with greater than 300 missing values (N=125) were excluded from the analysis. Using nearest neighbor methods, we imputed the lipid species missing less than 300 values. We used Volpara 1.5 (Volpara Health®) to quantify volumetric measures of MBD - volumetric percent density (VPD), dense volume (DV), and non-dense volume (NDV). We investigated the associations of the lipid species with MBD measures using multivariable linear regression models adjusting for age, age at menarche, body shape at age 10, race/ethnicity, body fat %, family history of breast cancer, oral contraceptive use, parity/age at first birth, and alcohol use. MBD measures were log10-transformed, and lipid species were standardized. Linear coefficients were back-transformed to the original scale and considered significant if the Bonferroni corrected p<0.05. Results: In multivariable linear regression models, 34 lipid species were inversely associated with VPD. The lipid species belong to the triacylglycerol (TAG, N=26), diacylglycerol (DAG, N=6), phosphatidylcholine (PC, N=1), and cholesterol ester (N=1) pathways. DAG(16:0/18:2) and TAG54:6-FA20:4 displayed the largest inverse associations with one standard deviation increase in DAG(16:0/18:2), and TAG54:6-FA20:4 corresponding to 9.9% (p=0.002), and 9.6% (p=0.007) decrease in VPD, respectively. Eleven lipid species were significantly associated with NDV, with 10 species (all TAG) having a positive association and 1 inverse association PC(18:1/18:1). The strongest positive association was observed with TAG54:6-FA20:4. One standard deviation increase in TAG54:6-FA20:4 was associated with a 9.8% increase in NDV (p=0.01). Several of the lipid species (N=8, 23.5%) that were associated with VPD were also associated with NDV, but in opposite directions. No lipid species were significantly associated with DV. Conclusions: Our study identified many lipid species, especially in TAG and DAG pathways, that were associated with VPD and NDV and offer new insights into the biological mechanisms underlying high MBD in premenopausal women. Future studies are needed to validate our results and the translational potential. Citation Format: Kayla R. Getz, Myung S. Jeon, Chongliang Luo, Jingqin Luo, Adetunji T. Toriola. Lipidome of mammographic breast density in premenopausal women. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4173.

Abstract Introduction: Lipids are important for many cellular processes and have been implicated in cancer development. Adopting a lipidomic approach has revealed sex-specific differences in lipid species but whether there are racial differences in lipid profiles remain unexplored. As a result, we investigated differences in lipid species between Non-Hispanic Black (NHB) vs Non-Hispanic White (NHW) women. Methods: We performed lipidomic profiling on 705 premenopausal women who were recruited during their annual screening mammogram at Washington University School of Medicine, St. Louis, MO. A total of 982 lipid species were profiled at Metabolon (Durham, NC®). 125 lipid species missing in 300 or more women were excluded from the analysis. For the remaining missing values, we employed the nearest neighbor method for imputation. We investigated the race-differentiating lipid species concentrations using linear regression models, adjusting for age and body mass index (BMI). To satisfy the assumptions of normality and homoscedasticity, we log-transformed the lipid concentrations before performing regression analyses. The linear regression coefficients were then back-transformed as percentage differences. We accounted for multiple testings by applying the Bonferroni correction. Statistical significance was defined as a Bonferroni-adjusted p-value < 10−5. Pathway enrichment analyses was conducted for differential lipid species for each sub pathway. Results: Of the 705 women, 506 were NHW and 163 were NHB. In analysis adjusted for age and BMI, 278 lipid species were significantly lower in NHB, and one lipid specie (TAG58:10-FA20:4) was higher in NHB. These species belonged to triacylglycerols (TAG, n=213), phosphatidylcholines (PC, n=25), diacylglycerols (DAG, n=22), cholesteryl esters (CE, n=4), phosphatidylethanolamines (PE, n=4), lysophosphatidylcholines (LPC, n=3), lysophosphatidylethanolamines (LPE, n=3), sphingomyelins (SM, n=2), ceramides (CER, n=1), lactosylceramides (LCER, n=1) and phosphatidylinositols (PI, n=1) sub-pathways. The TAG sub-pathway was enriched with differential lipid species (213 significant out of 518 species, p = 1.26 × 10−11). Forty-three lipid species (42 TAGs and one DAG) exhibited an absolute percentage difference > 50% between NHB and NHW women. The top 3 TAG species with the largest absolute percentage differences were TAG44:0-FA14:0 (60.6% lower in NHB women, p = 6.25 × 10−8), TAG46:2-FA16:1 (59.8% lower in NHB women, p = 1.11 × 10−14) and TAG47:2-FA16:1 (59.4% lower in NHB women, p = 8.66 × 10−20). Conversely, TAG58:10-FA20:4 was 47.1% (p = 5.79 × 10−8) higher in NHB women. Conclusions: Our study reveals novel substantial racial differences in lipid species among women, mostly in the TAG sub-pathway, highlighting the influence of race on the lipidome. Validation in a different study population is needed. Citation Format: ang Li, Ghazaleh Pourali, Kayla R. Getz, Myung Sik Jeon, Jingqin Luo, Chongliang Luo, Adetunji T. Toriola. Untargeted lipidomics reveals racial differences in lipid species among women [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2140.

Abstract Background: Identifying pathways that can be targeted to reduce breast density and breast cancer incidence is an unmet need, especially in premenopausal women. Receptor activator of nuclear factor-κB ligand (RANKL) signaling mediates the major proliferative response of mammary epithelium to progesterone and is positively associated with breast density but there are no clinical trial data on the impact of RANKL inhibition on breast tissue markers in women with dense breasts. We, therefore, determined the impact of RANKL inhibition on breast tissue gene expression in high-risk premenopausal women with dense breasts. Study design: Pilot phase I clinical trial of 9 healthy high-risk pre-menopausal women (≥35 years of age) with dense breasts performed at Washington University School of Medicine, St. Louis, MO from July 2018-December 2018. Fifty-five percent of participants had a positive family history of breast cancer in a first degree relative. Intervention: Participants were given a single dose of subcutaneous RANKL antibody, denosumab (60mg), at baseline (Day 1). On the same day, prior to the denosumab injection, participants had an ultrasound guided core needle biopsy and a blood draw. All study participants returned for repeat core needle biopsy and blood draw after 60 days (Day 60). Outcome Measures: Changes in breast tissue gene expression between Day 1 and Day 60 with a focus on immune/inflammatory and hormone markers. Gene expression was profiled using NanoString nCounter platform. We performed pathway enrichment analysis and used Cell Maker Enrichment library from EnrichR to identify differentially expressed genes. Genes with a p-value<0.05 on differential expression analysis were considered statistically significant for utilization in pathway enrichment analysis. Libraries utilized for pathway enrichment using the EnrichR platform included the ChEA transcription factor library, GO Biological Process library, and Cellular Components library. Results: Macrophage markers, including CCR5, CD86, CD300A, and CD84 and targets downstream of IRF8: (p-value =4.73e-7), neutrophil degranulation/neutrophil activation in the immune response (p-value=6.0e-21), and the secretory granule membrane pathways (p-value=2.4e-14) were downregulated in breast tissues on Day 60. Pathways involved in progesterone metabolism (p-value=0.0003), estrogen response (p-value=0.0014) and fatty acid metabolism, (p-value=0.0001) were significantly upregulated on Day 60. Specifically, genes involved in steroid hormone metabolism such as DHRS2 (p-value=3.13e-05), and AKR1B15: p-value=4.12e-05) were upregulated on Day 60. Conclusions: A single 60 mg dose of subcutaneous denosumab injection was associated with alterations in pathways involved in hormone, immune and inflammatory signaling in the breast tissues of healthy premenopausal women with dense breasts. Citation Format: Michael Waters, Kay Jayachandran, Debbie Bennet, Jin Zhang, Katherine Weilbaecher, Ian S. Hagemann, Graham A. Colditz, Catherine M. Appleton, Adetunji T. Toriola. Pilot phase I clinical trial of RANKL inhibition and breast tissue gene expression in high-risk premenopausal women with dense breasts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2206.

Reduced glutathione (GSH) is an endogenous disulfide bond reducer present in mammalian oocytes. It plays a critical role in sperm decondensation following fertilization, disrupting the protamine bonds that sustain the hypercondensed state of sperm DNA. However, disulfide bond reduction needs to be followed by protamine removal to achieve male pronuclear formation. In humans, heparan sulfate (HS) has been shown to exert this role (Romanato et al. 2008 Hum. Reprod. 23, 1145–1450). Although there are no reports in bovine, we recently demonstrated the presence of HS in cow oocytes by indirect immunofluorescence, using a specific anti-HS monoclonal antibody (Canel et al. 2015, Proc. SSR 48th Annual Meeting). Heparinases are known to cleave HS chains selectively, leading to its depolymerization. In the present work, we analysed the possible role of HS as protamine acceptor after fertilization in cattle. To this aim, we directly injected heparinase into the cytoplasm of IVF presumptive zygotes, and analysed its effect on pronuclei formation. Cumulus-oocyte complexes were collected from slaughtered cow ovaries and matured in vitro under standard conditions (Canel et al. 2012 Cell. Div. 7, 23–33). After 21 h, IVF was performed following Brackett and Oliphant’s protocol (1975 Biol. Reprod. 12, 260–274), using frozen–thawed semen from 1 or 2 bulls at a final concentration of 15 × 106 spermatozoa/mL (5 replicates). After 5 h of incubation, cumulus cells and sperm bound to zona pellucidae were removed from presumptive zygotes. Heparinase III solution (H8891, Sigma, St. Louis, MO, USA) was diluted in 50% (vol/vol) polyvinylpyrrolidone solution in PBS-(polyvinylpyrrolidone) at a final concentration of 50 U mL−1 and ~30 pL was mechanically injected into the cytoplasm of each IVF presumptive zygote (Hep group) using a 9-μm inner diameter injection pipette. A group of zygotes was injected with the same volume of 10% polyvinylpyrrolidone (sham), whereas others were not subjected to injection (control). All zygotes were cultured for 16 h from the beginning of IVF in SOF medium (Holm et al. 1999 Theriogenology 52, 693–700). For pronuclear formation assessment, presumptive zygotes were permeabilized with 0.2% Triton X-100 for 15 min at room temperature, and their DNA content was stained with 5 µg mL−1 propidium iodide and observed under an epifluorescence microscope. Zygotes showing 2 pronuclei (PN) were considered as synchronically fertilized, whereas those showing one PN and one condensed sperm head were considered as asynchronically fertilized. Data were analysed by Fisher’s exact test (P < 0.05). The rate of IVF zygotes showing 2 PN was lower for the Hep group (60.3%, n = 131) than those from sham (94.1%, n = 119) and control groups (98%, n = 101), which did not differ between them (P < 0.05). In conclusion, our results show for the first time that HS is involved in bull chromatin sperm decondensation and allow us to propose HS as a putative protamine acceptor during male pronucleus formation after IVF in cattle. Given the high frequency of sperm decondensation failure observed in bovine after intracytoplasmic sperm injection, this work provides new insights for the development of novel sperm/egg treatments that might improve intracytoplasmic sperm injection outcomes in cattle.

Abstract Introduction: Mammographic breast density (MBD), a strong predictor of breast cancer risk, is highly influenced by body mass index (BMI) in childhood and early adulthood, but the mechanisms elucidating this relationship are undetermined. To our knowledge, no study has explored the mediating role of biomarkers on the relationship between early-life adiposity and MBD. The goal of this study is to discover metabolites that mediate the relationship between BMI at ages 10 and 18 with MBD in premenopausal women. Methods: This study includes premenopausal women who had their screening mammogram at Washington University in St. Louis, MO, and provided a fasting blood sample. Metabolon performed untargeted metabolomic profiling, detecting 1,074 metabolites. Metabolites missing &gt;300 observations were excluded, leaving 828 metabolites; the other missing values were imputed using the nearest neighbor method. To mitigate batch effect, we normalized the metabolite peak area data using ComBat. Volumetric percent density (VPD) was calculated in 700 women using Volpara software. BMI at age 10 was estimated using the Stunkard pictogram, and BMI at age 18 was calculated from self-reported weight at 18 and height at study initiation. To assess the mediating role of the 828 metabolites, we performed high dimensional mediation analysis using the hima R package adjusting for potential confounders. Missing values in the covariates and BMI measures included in the mediation analysis were imputed using multivariate imputation by chain equations. Associations were considered significant if FDR p-value &lt;0.1. Results: Four metabolites (glutamate, beta-cryptoxanthin, phytanate, and cortolone glucuronide (1)) mediated the relationship between BMI at age 10 and VPD; and 2 metabolites (glutamate, beta-cryptoxanthin) mediated the relationship between BMI at age 18 and VPD. Glutamate and beta-cryptoxanthin significantly mediated the relationship between both BMI measures and VPD, but glutamate was the strongest mediator across both time points. Glutamate mediated 6.7% (FDR p-value=0.06) and 9.3% (FDR p-value=0.008) of the total effect between BMI at age 10 and 18, respectively, on VPD. Beta-cryptoxanthin mediated 4.1% (FDR p-value=0.06) and 6.3% (FDR p-value=0.04), of the total effect between BMI at age 10 and 18, respectively, on VPD. Additionally, phytanate mediated 2.6% (FDR p-value=0.06) and cortolone glucuronide (1) mediated 2.0% (FDR p-value=0.07) of the total effect between BMI at age 10 and VPD. Conclusion: Amino acid, lipid, cofactor/vitamin, and xenobiotic metabolites mediated the associations of BMI in early-life and VPD in premenopausal women. This innovative study offers insight into the biological mechanisms underlying the link between early-life adiposity and MBD, which can support future research into breast cancer prevention. Citation Format: Kayla R. Getz, Myung Sik Jeon, Lili Liu, Lei Liu, Chongliang Luo, Jingqin Luo, Adetunji T. Toriola. Using metabolomics to identify biomarkers mediating the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3429.